Article Information
History
- April 1, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Marcelo Lima Ribeiro1,2,*,†,
- Núria Profitós-Pelejà1,*,
- Juliana Carvalho Santos1,*,
- Pedro Blecua3,
- Diana Reyes Garau1,
- Marc Armengol1,4,
- Miranda Fernández-Serrano1,4,
- Hari P. Miskin5,
- Francesc Bosch4,6,7,
- Manel Esteller3,8,9,
- Emmanuel Normant5,† and
- Gael Roué1,4,6,7
- 1Lymphoma Translational Group, Josep Carreras Leukemia Research Institute, Badalona, Spain
- 3Cancer Epigenetics Group, Josep Carreras Leukemia Research Institute, Badalona, Spain
- 2Laboratory of Immunopharmacology and Molecular Biology, Sao Francisco University Medical School, Braganca Paulista, São Paulo, Brazil
- 4Autonomous University of Barcelona, Barcelona, Spain
- 5TG Therapeutics, New York, NY, USA
- 6Department of Hematology, Vall d’Hebron University Hospital, Barcelona, Spain
- 7Experimental Hematology, Vall d’Hebron Institute of Oncology, Barcelona, Spain
- 8Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Barcelona, Spain
- 9Instituciò Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
- ↵†Corresponding authors:
Marcelo L. Ribeiro, PhD. Lymphoma Translational Group, IJC. Ctra de Can Ruti, Camí de les Escoles s/n, 08916 Badalona (Barcelona), SPAIN. Tel: (+34) 93 5572800 Ext. 4081. E-mail: mlima{at}carrerasresearch.org; Emmanuel Normant, Pharm.D., PhD., Vice president preclinical sciences, TG Therapeutics, 2 Gansevoort street, New York, NY, 10014, USA, Tel: 1-781-813-9481. E-mail: enormant{at}tgtxinc.com.
↵* MLR, NPP and JCS contributed equally to this work.